SCHEMBL4327693

SCHEMBL4327693

CCCn1c(=O)c2c(nc(Cc3ccccc3)n2CCN(CC)CCO)n(CCc2ccc(NC(=O)CC(N)(CCCCCCN)C(=O)O)cc2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.44
ADORA2B P29275 6/20 0.37
MAPT P10636 4/20 0.36
TSHR P16473 3/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ADORA2A P29274 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ADORA3 P0DMS8 3/20 0.34
CYP3A4 P08684 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
TP53 P04637 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5834314 0.93 ADORA1 (0.42) ADORA1ADORA2BMAPTTSHRALDH1A1
SCHEMBL4165169 0.90 ADORA1 (0.48) ADORA1ADORA2BMAPTTSHRALDH1A1
SCHEMBL1333414 0.89 ADORA1 (0.48) ADORA1ADORA2BMAPTTSHRALDH1A1
SCHEMBL1333808 0.88 MAPT (0.36) ADORA1ADORA2BMAPTTSHRALDH1A1
SCHEMBL5836422 0.84 ADORA1 (0.39) ADORA1ADORA2BTSHRKMT2ASMN1; SMN2
SCHEMBL4171967 0.84 ADORA1 (0.49) ADORA1ADORA2BMAPTTSHRALDH1A1
SCHEMBL4182204 0.84 ADORA1 (0.43) ADORA1ADORA2BMAPTTSHRALDH1A1
SCHEMBL1334308 0.81 ADORA1 (0.57) ADORA1ADORA2BTSHRALDH1A1SMN1; SMN2
SCHEMBL4183579 0.81 ADORA1 (0.43) ADORA1ADORA2BTSHRALDH1A1KMT2A
SCHEMBL1332408 0.80 ADORA1 (0.66) ADORA1ADORA2BTSHRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090068101-A9 A1 Adenosine Receptor Antagonists ENDACEA, INC. (US) 2009-03-12 US disclosed
US-20070274910-A1 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility ENDACEA, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070274910-A1 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility HRH3, HRH1, HRH2 ADORA1 4/4885ADORA2B 9/4885MAPT 4646/4885
US-20090068101-A9 A1 Adenosine Receptor Antagonists ADORA1, ADORA3, ADORA2A ADORA1 1/4885ADORA2B 4/4885MAPT 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.